JPMorgan initiated coverage of Amrize (AMRZ) with an Overweight rating and $57 price target representing 13% upside potential. The firm says the company’s “robust” EBITDA growth prospects and “strong” free cash flow conversion rate of over 50% make it an attractive investment. Amrize has a proven track record on acquisitions, which opens opportunities for capital allocation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ: